Biosergen provides Phase 2 clinical development strategy update
Stockholm, Sweden – March 29, 2023 – Biosergen AB (“Biosergen” or the “Company”), today announced an update of the Company’s Phase 2 clinical trial development strategy. Based on the data from the completed Phase I trial, showing no severe side effects associated with BSG005, Biosergen will initiate a Phase 2 trial to show BSG005’s potential to challenge Amphotericin B’s role as a last resort antifungal treatment, as well as to de-risk the further development path of BSG005.Biosergen is pleased to announce its plans to initiate its first Phase 2 clinical trial towards the end of Q2 2023.